Sign Up to like & get
recommendations!
1
Published in 2022 at "Cancer Research"
DOI: 10.1158/0008-5472.can-21-2997
Abstract: This detailed preclinical investigation, including pharmacokinetics/pharmacodynamics and dose–schedule optimizations, of AZD6738/ceralasertib alone and in combination with chemotherapy or PARP inhibitors can inform ongoing clinical efforts to treat cancer with ATR inhibitors.
read more here.
Keywords:
azd6738 ceralasertib;
chemotherapy parp;
combination chemotherapy;
inhibitor ... See more keywords